MedPlus Health Services Limited
MEDPLUS.NS
National Stock Exchange of India822.15
INR
+0.15
- -
MedPlus Health Services Limited
MEDPLUS.NS
(National Stock Exchange of India)
Recent
price
822.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- MedPlus Health Services Limited (MEDPLUS.NS) operates as an integrated pharmacy retail chain in India, offering a comprehensive range of pharmaceutical and wellness products through its extensive network of stores and digital platforms. The company provides prescription and over-the-counter medicines, including generic and branded drugs; consumer health products such as vitamins, supplements, personal care items, and baby care essentials; beauty and cosmetics under its own brands like Sugar Cosmetics and NewU; and healthcare services including diagnostic tests, teleconsultations, and clinic operations. It also sells fast-moving consumer goods (FMCG), groceries, and ayurvedic products, primarily targeting individual consumers, households, and small clinics across urban, semi-urban, and rural markets in India. Founded in 2006 and headquartered in Hyderabad, Telangana, MedPlus conducts its operations nationwide with over 4,000 stores as of late 2025, supplemented by its online marketplace MedPlus Mart and a B2B distribution arm serving hospitals and pharmacies. The company serves as one of India's largest organized pharmacy retailers by store count and revenue, focusing on supply chain efficiency, private-label generics, and digital health integration to enhance accessibility in the retail pharmacy and healthcare services segments. In recent developments, MedPlus expanded its footprint through aggressive store additions, reaching approximately 4,150 outlets by Q2 FY2026, and strengthened its digital ecosystem with enhanced app features for home delivery and subscriptions. The company reported robust financial performance in FY2025, including revenue growth of over 20% year-over-year driven by omnichannel strategies, and launched new private-label offerings in nutraceuticals and dermatology categories. Additionally, it pursued strategic B2B growth via acquisitions of regional distributors and partnerships for diagnostic services, marking a shift toward integrated healthcare delivery amid India's expanding retail pharmacy market.